Skip to main content

Table 2 Comparison of clinical features, treatment details, and outcomes between patients with autoimmune pancreatitis and chronic pancreatitis

From: Extracorporeal shock wave lithotripsy treatment of pancreatic stones complicated with advanced stage autoimmune pancreatitis

  AIP (n = 8) CP (n = 92) Pvalue
Clinical features Median (range)  
 Age (years) 69.0 (59–73) 56.5 (20–85) 0.018*
 Gender (male/female) 7/1 77/15 1.000
 Therapeutic purpose for ESWL    
  Chronic pain (+/−) 0/8 42/50 0.019*
  Pancreatic attack (+/−) 1/7 32/60 0.265
  Preservation of pancreatic function (+/−) 7/1 18/74 <0.001*
Treatment details    
 Location of treated pancreatic stones    
  Pancreatic head 6/2 83/9 0.213
  Pancreatic body 3/5 15/77 0.153
  Pancreatic tail 0/8 1/91 1.000
 Pancreatic duct stenosis proximal to stones (+/−) 4/4 22/70 0.107
 Endoscopic treatment 6/2 66/26 1.000
  Endoscopic pancreatic sphincterotomy (+/−) 3/5 39/53 1.000
  Endoscopic pancreatolithotripsy (+/−) 3/5 45/47 0.716
  Endoscopic pancreatic stenting (+/−) 3/5 32/60 1.000
Outcomes    
 Extraction of pancreatic stones in MPD (+/−) 5/3 71/21 0.394
 Shift to surgical treatment (+/−) 1/7 3/89 0.284
 Complications associated with ESWL (+/−) 0/8 8/84 1.000
 Relapse of pancreatic stones in MPD (+/−) 1/7 22/70 0.678
  1. AIP: autoimmune pancreatitis; CP; chronic pancreatitis; ESWL: extracorporeal shock wave lithotripsy; MPD: main pancreatic duct.
  2. *P < 0.05.
\